Transdermal Drug Delivery Systems: Mechanistic Insights, Technological Advances, And Clinical Applications

Abstract

Transdermal drug delivery systems (TDDS) have emerged as a sophisticated, patient-centred strategy for systemic and localized drug administration through intact skin. By circumventing hepatic first-pass metabolism and gastrointestinal degradation, TDDS offer enhanced bioavailability, prolonged therapeutic action, and improved patient compliance relative to conventional oral and parenteral routes. Although the skin's large surface area and accessibility make it an attractive delivery portal, its highly organized lipid–protein architecture, principally that of the stratum corneum, imposes a formidable barrier that restricts the permeation of most therapeutic molecules. The performance of TDDS is governed by controlled drug release, concentration-gradient-driven diffusion, and selective targeting of systemic or local tissues. Drug transport proceeds via transcellular, intercellular, and appendageal pathways and is dictated by physicochemical properties such as molecular weight, lipophilicity, ionization state, and thermodynamic activity, together with physiological variables including skin hydration, temperature, and anatomical site of application. Passive transdermal delivery remains restricted to a narrow range of small, lipophilic, and potent drugs, whereas active transdermal technologies have substantially broadened the therapeutic landscape. Recent advances in chemical penetration enhancers, nanocarrier-based systems, iontophoresis, sonophoresis, electroporation, and, in particular, microneedle-assisted platforms have enabled efficient delivery of hydrophilic drugs, peptides, proteins, and vaccines that were previously incompatible with transdermal administration. Integration of nanosystems such as liposomes, ethosomes, and polymeric nanoparticles further improves drug stability, solubility, and controlled-release kinetics, while the emergence of smart, stimulus-responsive TDDS capable of modulating drug flux in response to physiological signals marks a paradigm shift toward precision and personalized medicine. Despite this progress, challenges persist in large-scale manufacturing, regulatory harmonization, inter-individual variability in skin permeability, and the long-term safety of enhancement strategies. Nonetheless, the convergence of pharmaceutical sciences, materials engineering, and biomedical microfabrication continues to transform TDDS into versatile, non-invasive platforms for chronic disease management, immunotherapy, and metabolic disorders. This review comprehensively examines skin anatomy and permeation mechanisms, the principles of TDDS design, passive and active delivery strategies, formulation components, influencing factors, clinical applications, and emerging technologies, underscoring the evolving role of transdermal systems as a cornerstone of next-generation drug delivery.